In addition, the ESTIMATE and GSEA analysis also corroborated previous results that high-risk group had significantly higher immune and tumor scores with multiple immune-related gene sets enrichment compared to low-risk group, including complement, IL2-STAT5 signaling, IL6-JAK-STAT3 signaling, interferon-alpha response, interferon-gamma response, TGF-BETA signaling and TNFA signaling via NFKB. The gene discussed is TGFB1; the disease is neoplasm.